The prognostic value of combined tumor markers and systemic immune-inflammation index in colorectal cancer patients

Xie, Hailun; Yuan, Guanghui; Huang, Shizhen; Kuang, Jiaan; Yan, Ling; Ruan, Guo‐Tian; Tang, Shaohui; Gan, Jialiang

doi:10.1007/s00423-020-01963-3

Cited by 7 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with malignant tumors, neutrophils are inflammatory cells that indicate that the patient's systemic level of inflammation is increased, which is conducive to the local tissue angiogenesis of tumors, which in turn promotes the proliferation and metastasis of CRC cells (13). Additionally, this systemic inflammation also promotes an increase in intestinal permeability, which in turn leads to the studies have confirmed that an increased SII index score is the main risk factor for the poor postoperative prognosis of CRC patients, which supports the findings of this study (16)(17)(18)(19)(20). However, compared to previous studies, this study is somewhat innovative; we did not find any other study that explored the relationship between the SII index and postoperative infectious complications in CRC patients, and this study confirmed that an increased SII index score indicates an increased incidence of postoperative infectious complications.…”

Section: Discussionsupporting

confidence: 85%

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Feng¹,

Xu²,

Lin³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract. Surgery is the main way to cure CRC, but the postoperative complication rate and recurrence rate remain high. The systemic immune-inflammation (SII) index reflects a patient's systemic inflammatory state and immune state. Postoperative recurrence and the occurrence of complications are closely related to the inflammatory state and immune state. Thus, the SII index may have some value in predicting postoperative complications and the long-term prognosis of CRC patients, but relevant studies are currently lacking. The present study sought to examine the effect of the SII index on the postoperative complications and long-term prognosis of patients with CRC.Methods: From January 2014 to January 2017, the data of 440 patients with CRC who had been admitted to the Affiliated Hospital of Guangdong Medical University were retrospectively collected, and the patients were equally divided into the high and the low SII groups according to their preoperative SII index levels.The postoperative complication rate and postoperative progression-free survival (PFS) and mortality between the 2 groups were compared.Results: Compared to the low SII group, the incidence of postoperative infection in the high SII group was significantly increased (15.45% vs. 9.09%, P=0.042), mortality was significantly increased at 5 years postoperatively (20.91% vs. 7.27%, P<0.001), and PFS was significantly shortened (P<0.001). The SII index had certain predictive value for postoperative infection in CRC patients, and the area under the curve (AUC) was 0.645 [95% confidence interval (CI): 0.559-0.731, P=0.001]. The SII index also had certain predictive value for the progression of CRC patients within 5 years of surgery, and the AUC was 0.670 (95% CI: 0.610-0.729, P<0.001). Additionally, the SII index had certain predictive value for death within 5 years of surgery in patients with CRC, and the AUC was 0.660 (95% CI: 0.593-0.726, P<0.001). CRC patients with postoperative infection had a significantly shorter PFS period than those who did not develop postoperative infection (P=0.029). Conclusions:The SII index has certain predictive value for the diagnosis of postoperative infectious complications and the long-term prognosis of CRC patients.

show abstract

Section: Discussionsupporting

confidence: 85%

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Feng¹,

Xu²,

Lin³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Systemic inflammatory responses are involved in the initiation, promotion, and metastasis of cancer cells [ 7 ]. In the recent years, the systemic immune-inflammation index (SII), which is calculated as platelet count × neutrophils/lymphocytes, has been reported as a noninvasive prognostic marker for various solid tumors [ 8 , 9 ]. The prognostic value of SII in patients with pancreatic cancer has also been explored by many researchers [ 10 – 15 ]; however, the results are conflicting.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

Shui

et al. 2021

Aging

View full text Add to dashboard Cite

The prognostic value of the systemic immune-inflammation index (SII) in patients with pancreatic cancer is conflicting according to previous investigations. Therefore, we performed a meta-analysis to explore the association between SII and pancreatic cancer prognosis. Electronic databases were searched for studies exploring the association of SII with prognostic outcomes in pancreatic cancer. The endpoints were overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters. The prognostic value of SII was estimated by hazard ratio (HR) or odds ratio (OR) with a 95% confidence interval (CI). Nine studies containing 11 cohorts with 2,365 subjects in total were included in this meta-analysis. Elevated SII was associated with poor OS (HR=1.50, 95% CI=1.15–1.96, p=0.002), RFS/PFS/DFS (HR=1.52, 95% CI=1.01–2.28, p=0.045), and CSS (HR=2.60, 95% CI=1.65–4.09, p < 0.001) in patients with pancreatic cancer. Additionally, there was no significant association between SII and other parameters in pancreatic cancer such as sex, tumor location, lymph node metastasis, tumor-node-metastasis stage, vascular invasion, and grade. This meta-analysis suggested that elevated SII was a significant prognostic marker for short-term and long-term survival outcomes in patients with pancreatic cancer.

show abstract

“…Haematological inflammatory parameters, such as neutrophils, lymphocytes, platelets and C‐reactive protein (CRP), can effectively reflect the systemic inflammatory state of cancer 9,10 . Many studies have evaluated several systemic inflammation biomarkers composed of these inflammatory parameters and demonstrated that these biomarkers have important prognostic predictive value in different cancers, including NSCLC 11–16 . However, it remains unclear which combination of inflammatory parameters is the optimal systemic inflammation biomarker to assess prognosis in patients with NSCLC.…”

Section: Introductionmentioning

confidence: 99%

“… 9 , 10 Many studies have evaluated several systemic inflammation biomarkers composed of these inflammatory parameters and demonstrated that these biomarkers have important prognostic predictive value in different cancers, including NSCLC. 11 , 12 , 13 , 14 , 15 , 16 However, it remains unclear which combination of inflammatory parameters is the optimal systemic inflammation biomarker to assess prognosis in patients with NSCLC. Therefore, this study aimed to compare the prognostic value of existing systemic inflammation biomarkers and determine the optimal systemic inflammation biomarker in patients with NSCLC through a multicentre prospective setting.…”

Section: Introductionmentioning

confidence: 99%

The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer

Xie

Ruan

Wei

et al. 2023

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

Background Systemic inflammation, the most representative tumour–host interaction, plays a crucial role in disease progression and prognosis in patients with non‐small cell lung cancer (NSCLC). Few studies have compared the performance of existing haematological systemic inflammation biomarkers in predicting the prognosis of NSCLC patients. The purpose of this study was to compare the prognostic value of existing systemic inflammation biomarkers and determine the optimal systemic inflammation biomarker in patients with NSCLC through a multicentre prospective study. Methods The predictive accuracy of systemic inflammation biomarkers for prognostic assessment in NSCLC was assessed using C‐statistics. Inter‐group differences in survival were assessed using the log‐rank test and visualized using the Kaplan–Meier method. A restricted cubic spline (RCS) curve was used to explore the association between the biomarkers and survival. Independent prognostic biomarkers for overall survival were determined using multivariable Cox proportional hazards regression analysis. Logistic regression analysis was used to determine independent predictors of 90‐day outcomes, length of hospitalization, hospitalization expenses and cachexia. Results The inflammatory burden index (IBI) had the highest C‐statistic for predicting the prognosis of patients with NSCLC, reaching 0.640 (0.617, 0.663). Patients with a high IBI had significantly worse outcomes than those with a low IBI (35.46% vs. 57.22%; log‐rank P < 0.001). The IBI was also able to differentiate the prognosis of patients with NSCLC with the same pathological stage. The RCS curve showed an inverted L‐shaped dose–response relationship between the IBI and survival of patients with NSCLC. Multivariable Cox proportional hazards regression analysis showed that a high IBI was an independent risk factor for death of patients with NSCLC (hazard ratio = 1.229, 95% confidence interval [CI]: 1.131–1.335, P < 0.001). A high IBI was an independent predictor of 90‐day outcomes (odds ratio [OR] = 1.789, 95% CI: 1.489–2.151, P < 0.001), prolonged hospital stays (OR = 1.560, 95% CI: 1.256–1.938, P < 0.001), high hospitalization expenses (OR = 1.476, 95% CI: 1.195–1.822, P < 0.001) and cachexia (OR = 1.741, 95%CI = 1.374–2.207, P < 0.001) in patients with NSCLC. Conclusions The IBI was independently associated with overall survival, 90‐day outcomes, length of hospitalization, hospitalization expenses and cachexia in NSCLC patients. As an optimal systemic inflammation biomarker, the IBI has broad clinical application prospects in predicting the prognosis of patients with NSCLC.

show abstract

The prognostic value of combined tumor markers and systemic immune-inflammation index in colorectal cancer patients

Cited by 7 publications

References 32 publications

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study

Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer

Contact Info

Product

Resources

About